Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucatinib - Array BioPharma/Seagen

X
Drug Profile

Tucatinib - Array BioPharma/Seagen

Alternative Names: ARRY 380; Irbinitinib; MK 7119; ONT 380; TUKYSA

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Criterium; Merck & Co; Merck Sharp & Dohme; Novartis; Seagen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Oxazoles; Pyridines; Quinazolines; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists; Phosphorylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; HER2 positive breast cancer
  • Phase II/III Gastrointestinal cancer
  • Phase II Biliary cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase I/II Cholangiocarcinoma; Gallbladder cancer

Most Recent Events

  • 31 May 2024 Final efficacy and adverse events data from the phase II MOUNTAINEER trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Updated efficacy and adverse events data from the phase II BASKET trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 17 Apr 2024 Seagen completes the MOUNTAINEER-02 phase II/III trial in Gastrointestinal cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Canada, Australia, South Korea, Taiwan, United Kingdom (PO) (NCT04499924)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top